What have we learned from cancer immunotherapy in the last 3 years?

@inproceedings{Ascierto2014WhatHW,
  title={What have we learned from cancer immunotherapy in the last 3 years?},
  author={Paolo Antonio Ascierto and Francesco M. Marincola},
  booktitle={Journal of Translational Medicine},
  year={2014}
}
Until recently, most immunotherapeutic approaches used to fight cancer were ineffective, counteracted by the tumour’s ability to evade immune attack. However, extensive research has improved our understanding of tumour immunology and enabled the development of novel treatments that can harness the patient’s immune system and prevent immune escape. Over the last few years, through numerous clinical trials and real-world experience, we have accumulated a large amount of evidence regarding the… CONTINUE READING

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Thyroid disorders induced by checkpoint inhibitors

  • Reviews in Endocrine and Metabolic Disorders
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies

  • International journal of molecular sciences
  • 2019
VIEW 3 EXCERPTS
CITES BACKGROUND

Enhancement of NK cells proliferation and function by Shikonin.

Yan Li, Hailin Lu, +5 authors Min Tao
  • Immunopharmacology and immunotoxicology
  • 2017
VIEW 3 EXCERPTS
CITES RESULTS & BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 76 REFERENCES

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract

FS Hodi, SL Topalian, +7 authors M Sznol
  • Eur J Cancer 2013,
  • 2013
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  • The New England journal of medicine
  • 2012
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Improved survival with ipilimumab in patients with metastatic melanoma.

  • The New England journal of medicine
  • 2010
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

AM Di Giacomo, L Calabrò, +10 authors M Maio
  • Cancer Immunol Immunother
  • 2013
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL